This is the authors' abstract. We don't add key points for this paper.
We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: